Research graph
References from Plasma multi-omics reveals molecular remodeling and prognostic biomarkers in advanced breast cancer treated with trastuzumab deruxtecan. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting HER2-positive breast cancer: advances and future directions
10.1038/s41573-022-00579-0 · 2023 · External reference
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
10.1016/j.esmoop.2024.102989 · 2024 · External reference
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
10.1056/nejmoa2203690 · 2022 · External reference
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
10.1038/s41467-025-58266-8 · 2025 · External reference
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
10.1038/s41523-025-00748-5 · 2025 · External reference
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
10.1007/s12282-024-01600-7 · 2024 · External reference
Trastuzumab deruxtecan (T-DXd) resistance via loss of HER2 expression and binding
10.1158/2159-8290.cd-25-0647 · 2026 · External reference
Summary of research: Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02
10.1007/s12325-024-03080-9 · 2025 · External reference
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
10.1186/s12885-024-11851-4 · 2024 · External reference
Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial
10.1186/s13058-025-02137-z · 2025 · External reference
Metabolomics and metabolites in cancer diagnosis and treatment
10.1186/s43556-025-00362-8 · 2025 · External reference
Multi-omics strategies for biomarker discovery and application in personalized oncology
10.1186/s43556-025-00340-0 · 2025 · External reference
Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis
10.1080/2162402x.2015.1093722 · 2016 · External reference
Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer
10.1038/s41598-023-49441-2 · 2023 · External reference
Complement in tumourigenesis and the response to cancer therapy
10.3390/cancers13061209 · 2021 · External reference
The prowess of metabolomics in cancer research: current trends, challenges and future perspectives
10.1007/s11010-024-05041-w · 2025 · External reference
HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers
10.18632/aging.205779 · 2024 · External reference
Leucine metabolism in T cell activation: mTOR signaling and beyond
10.3945/an.115.011221 · 2016 · External reference
CD47-SIRPα-targeted therapeutics: status and prospects
10.1016/j.iotech.2022.100070 · 2022 · External reference
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · 2013 · External reference
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer
10.1186/s13046-024-03143-3 · 2024 · External reference
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
10.1186/s13045-025-01752-9 · 2025 · External reference
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs
10.1038/s41467-025-64675-6 · 2025 · External reference
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
10.1186/s40425-017-0308-4 · 2017 · External reference
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
10.1016/s1470-2045(24)00581-3 · 2025 · External reference
Systematic review and meta-analysis of C-reactive protein as a biomarker in breast cancer
10.1080/10408363.2022.2050886 · 2022 · External reference
Antibody-drug conjugates: the new frontier of chemotherapy
10.3390/ijms21155510 · 2020 · External reference
Mechanisms of resistance to antibody-drug conjugates
10.3390/ijms24119674 · 2023 · External reference
DS-8201a, a novel HER2-targeted ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1
10.1158/1078-0432.ccr-15-2822 · 2016 · External reference
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
10.1038/s41392-020-00326-0 · 2020 · External reference
Lactate and lactylation in cancer
10.1038/s41392-024-02082-x · 2025 · External reference
Antibody-drug conjugates to promote immune surveillance: lessons learned from breast cancer
10.3390/biomedicines12071491 · 2024 · External reference
The prowess of metabolomics in cancer research: current trends, challenges and future perspectives
10.1007/s11010-024-05041-w · ExternalCitation · doi-reference
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
10.1007/s12282-024-01600-7 · ExternalCitation · doi-reference
Summary of research: Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02
10.1007/s12325-024-03080-9 · ExternalCitation · doi-reference
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
10.1016/j.esmoop.2024.102989 · ExternalCitation · doi-reference
CD47-SIRPα-targeted therapeutics: status and prospects
10.1016/j.iotech.2022.100070 · ExternalCitation · doi-reference
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
10.1016/s1470-2045(24)00581-3 · ExternalCitation · doi-reference
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
10.1038/s41392-020-00326-0 · ExternalCitation · doi-reference
Lactate and lactylation in cancer
10.1038/s41392-024-02082-x · ExternalCitation · doi-reference
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
10.1038/s41467-025-58266-8 · ExternalCitation · doi-reference
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs
10.1038/s41467-025-64675-6 · ExternalCitation · doi-reference
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
10.1038/s41523-025-00748-5 · ExternalCitation · doi-reference
Targeting HER2-positive breast cancer: advances and future directions
10.1038/s41573-022-00579-0 · ExternalCitation · doi-reference
Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer
10.1038/s41598-023-49441-2 · ExternalCitation · doi-reference
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · ExternalCitation · doi-reference
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
10.1056/nejmoa2203690 · ExternalCitation · doi-reference
Systematic review and meta-analysis of C-reactive protein as a biomarker in breast cancer
10.1080/10408363.2022.2050886 · ExternalCitation · doi-reference
Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis
10.1080/2162402x.2015.1093722 · ExternalCitation · doi-reference
DS-8201a, a novel HER2-targeted ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1
10.1158/1078-0432.ccr-15-2822 · ExternalCitation · doi-reference
Trastuzumab deruxtecan (T-DXd) resistance via loss of HER2 expression and binding
10.1158/2159-8290.cd-25-0647 · ExternalCitation · doi-reference
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
10.1186/s12885-024-11851-4 · ExternalCitation · doi-reference
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
10.1186/s13045-025-01752-9 · ExternalCitation · doi-reference
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer
10.1186/s13046-024-03143-3 · ExternalCitation · doi-reference
Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial
10.1186/s13058-025-02137-z · ExternalCitation · doi-reference
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
10.1186/s40425-017-0308-4 · ExternalCitation · doi-reference
Multi-omics strategies for biomarker discovery and application in personalized oncology
10.1186/s43556-025-00340-0 · ExternalCitation · doi-reference
Metabolomics and metabolites in cancer diagnosis and treatment
10.1186/s43556-025-00362-8 · ExternalCitation · doi-reference
HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers
10.18632/aging.205779 · ExternalCitation · doi-reference
Antibody-drug conjugates to promote immune surveillance: lessons learned from breast cancer
10.3390/biomedicines12071491 · ExternalCitation · doi-reference
Complement in tumourigenesis and the response to cancer therapy
10.3390/cancers13061209 · ExternalCitation · doi-reference
Antibody-drug conjugates: the new frontier of chemotherapy
10.3390/ijms21155510 · ExternalCitation · doi-reference
Mechanisms of resistance to antibody-drug conjugates
10.3390/ijms24119674 · ExternalCitation · doi-reference
Leucine metabolism in T cell activation: mTOR signaling and beyond
10.3945/an.115.011221 · ExternalCitation · doi-reference
